Bruce S. Chelberg
Directeur/Membre du Conseil chez Snap-on Tools Co. LLC
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Nicholas Pinchuk | M | 77 | 22 ans | |
William Lehman | M | 72 | 21 ans | |
June Lemerand | M | 62 | 19 ans | |
Thomas Ward | M | 71 |
Snap-on Tools Co. LLC
Snap-on Tools Co. LLC Tools & HardwareConsumer Durables Snap-on Tools Co. LLC manufactures tools & industrial equipment. The firm offers ten different sockets that would 'snap on' to five interchangeable wrench. The company was founded in 1920 and is headquartered in Kenosha, Wisconsin. | 17 ans |
Aldo Pagliari | M | 69 | 22 ans | |
Gregg Sherrill | M | 71 | 14 ans | |
Karen Daniel | F | 66 | 19 ans | |
Nathan Jones | M | 67 | 16 ans | |
James Holden | M | 72 | 15 ans | |
Henry Knueppel | M | 75 | 13 ans | |
Thomas L. Kassouf | M | 71 |
Snap-on Tools Co. LLC
Snap-on Tools Co. LLC Tools & HardwareConsumer Durables Snap-on Tools Co. LLC manufactures tools & industrial equipment. The firm offers ten different sockets that would 'snap on' to five interchangeable wrench. The company was founded in 1920 and is headquartered in Kenosha, Wisconsin. | 13 ans |
Iain Boyd | M | 61 | 17 ans | |
Irene S. Sudac | F | - | 14 ans | |
Timothy Chambers | M | 59 | 20 ans | |
Edward Rensi | M | 80 |
Snap-on Tools Co. LLC
Snap-on Tools Co. LLC Tools & HardwareConsumer Durables Snap-on Tools Co. LLC manufactures tools & industrial equipment. The firm offers ten different sockets that would 'snap on' to five interchangeable wrench. The company was founded in 1920 and is headquartered in Kenosha, Wisconsin. | - |
Kevin Thatcher | M | - | 14 ans | |
Maria Vieira | F | - | 13 ans | |
Sara Verbsky | F | - | 25 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Michael Scudder | M | 63 | 27 ans | |
Jack J. Kogut | M | 77 |
Northfield Laboratories, Inc.
Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | 15 ans |
Paul F. Clemens | M | 71 | 11 ans | |
Mark Sander | M | 65 | 11 ans | |
Jack D. Michaels | M | 86 | 11 ans | |
Robert Pohlad | M | 69 |
PepsiAmericas, Inc.
PepsiAmericas, Inc. Beverages: Non-AlcoholicConsumer Non-Durables PepsiAmericas, Inc. makes sells and delivers a broad portfolio of Pepsi-Cola core brands, Cadbury beverages and other national and regional brands in U.S. locations as well as Puerto Rico, Jamaica, Barbados, the Bahamas, Trinidad and Tobago, Poland, Hungary, the Czech Republic and the Republic of Slovakia. PepsiCo, Inc. holds a 57 percent equity interest in PepsiAmericas. The company was founded in 1962 and is headquartered in Minneapolis, MN. | 12 ans |
Miles L. Marsh | M | 76 |
Whitman Corp.
| - |
Barbara Boigegrain | F | 66 | 14 ans | |
Nicholas Chulos | M | 64 | 10 ans | |
Herbert M. Baum | M | 87 |
Whitman Corp.
PepsiAmericas, Inc.
PepsiAmericas, Inc. Beverages: Non-AlcoholicConsumer Non-Durables PepsiAmericas, Inc. makes sells and delivers a broad portfolio of Pepsi-Cola core brands, Cadbury beverages and other national and regional brands in U.S. locations as well as Puerto Rico, Jamaica, Barbados, the Bahamas, Trinidad and Tobago, Poland, Hungary, the Czech Republic and the Republic of Slovakia. PepsiCo, Inc. holds a 57 percent equity interest in PepsiAmericas. The company was founded in 1962 and is headquartered in Minneapolis, MN. | 15 ans |
Phupinder Gill | M | 63 | 12 ans | |
Martin Ellen | M | 70 |
Whitman Corp.
| 12 ans |
Susan F. Marrinan | F | 75 | 16 ans | |
Roxanne J. Decyk | F | 71 | 21 ans | |
Arthur L. Kelly | M | 85 | 34 ans | |
Robert A. Cornog | M | 83 | 11 ans | |
Irwin M. Shur | M | 66 | 10 ans | |
Richard F. Teerlink | M | 87 | 14 ans | |
Ellen Rudnick | F | 73 | 17 ans | |
Joseph W. England | M | 83 | 26 ans | |
Brother James Gaffney | M | 82 | 21 ans | |
John M. O'Meara | M | 78 | 26 ans | |
John L. Sterling | M | 79 | 18 ans | |
John E. Rooney | M | 81 | - | |
Peter Henseler | M | 65 | 11 ans | |
Patrick J. McDonnell | M | 80 | 16 ans | |
Cynthia A. Lance | F | 55 | - | |
John J. Hinds | M | - |
Northfield Laboratories, Inc.
Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | - |
John F. Fiedler | M | 86 | - | |
Steven A. Gould | M | 77 |
Northfield Laboratories, Inc.
Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | 16 ans |
Michael Small | M | 66 | 12 ans | |
Steven Robert Andrews | M | 71 |
PepsiAmericas, Inc.
PepsiAmericas, Inc. Beverages: Non-AlcoholicConsumer Non-Durables PepsiAmericas, Inc. makes sells and delivers a broad portfolio of Pepsi-Cola core brands, Cadbury beverages and other national and regional brands in U.S. locations as well as Puerto Rico, Jamaica, Barbados, the Bahamas, Trinidad and Tobago, Poland, Hungary, the Czech Republic and the Republic of Slovakia. PepsiCo, Inc. holds a 57 percent equity interest in PepsiAmericas. The company was founded in 1962 and is headquartered in Minneapolis, MN. | 2 ans |
Richard Strege | M | 66 | 14 ans | |
George A. Hides | M | 57 |
Northfield Laboratories, Inc.
Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | 14 ans |
Kevin Moffitt | M | 64 | - | |
John F. Chlebowski | M | 79 | 10 ans | |
Anup Ranjan Banerjee | M | 73 | 13 ans | |
J. Stephen Vanderwoude | M | 80 | 30 ans | |
Thomas J. Schwartz | M | 74 | 9 ans | |
Jack Olshansky | M | - |
Northfield Laboratories, Inc.
Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | - |
Brian K. Hamm | M | 50 |
PepsiAmericas, Inc.
PepsiAmericas, Inc. Beverages: Non-AlcoholicConsumer Non-Durables PepsiAmericas, Inc. makes sells and delivers a broad portfolio of Pepsi-Cola core brands, Cadbury beverages and other national and regional brands in U.S. locations as well as Puerto Rico, Jamaica, Barbados, the Bahamas, Trinidad and Tobago, Poland, Hungary, the Czech Republic and the Republic of Slovakia. PepsiCo, Inc. holds a 57 percent equity interest in PepsiAmericas. The company was founded in 1962 and is headquartered in Minneapolis, MN. | 10 ans |
John F. Bierbaum | M | 80 |
Northfield Laboratories, Inc.
Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | 7 ans |
Mark S. Pezzoni | M | 67 | - | |
W. Scott Nehs | M | - |
PepsiAmericas, Inc.
PepsiAmericas, Inc. Beverages: Non-AlcoholicConsumer Non-Durables PepsiAmericas, Inc. makes sells and delivers a broad portfolio of Pepsi-Cola core brands, Cadbury beverages and other national and regional brands in U.S. locations as well as Puerto Rico, Jamaica, Barbados, the Bahamas, Trinidad and Tobago, Poland, Hungary, the Czech Republic and the Republic of Slovakia. PepsiCo, Inc. holds a 57 percent equity interest in PepsiAmericas. The company was founded in 1962 and is headquartered in Minneapolis, MN. | 11 ans |
Alan T. Biland | M | 65 |
Snap-on Tools Co. LLC
Snap-on Tools Co. LLC Tools & HardwareConsumer Durables Snap-on Tools Co. LLC manufactures tools & industrial equipment. The firm offers ten different sockets that would 'snap on' to five interchangeable wrench. The company was founded in 1920 and is headquartered in Kenosha, Wisconsin. | - |
Bradley R. Lewis | M | - | - | |
Kenneth L. Johnsen | M | 62 |
PepsiAmericas, Inc.
PepsiAmericas, Inc. Beverages: Non-AlcoholicConsumer Non-Durables PepsiAmericas, Inc. makes sells and delivers a broad portfolio of Pepsi-Cola core brands, Cadbury beverages and other national and regional brands in U.S. locations as well as Puerto Rico, Jamaica, Barbados, the Bahamas, Trinidad and Tobago, Poland, Hungary, the Czech Republic and the Republic of Slovakia. PepsiCo, Inc. holds a 57 percent equity interest in PepsiAmericas. The company was founded in 1962 and is headquartered in Minneapolis, MN. | 14 ans |
Barbara H. Stephens | F | 65 |
Snap-on Tools Co. LLC
Snap-on Tools Co. LLC Tools & HardwareConsumer Durables Snap-on Tools Co. LLC manufactures tools & industrial equipment. The firm offers ten different sockets that would 'snap on' to five interchangeable wrench. The company was founded in 1920 and is headquartered in Kenosha, Wisconsin. | 11 ans |
Steven E. Fleck | M | - |
Northfield Laboratories, Inc.
Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | 7 ans |
Terry G. Beaudry | M | 75 | - | |
Jeff Sisson | M | 67 | 1 ans | |
Donna M. O'Neill | F | 63 |
Northfield Laboratories, Inc.
Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | 5 ans |
Richard M. Secor | M | - | - | |
Leslie H. Kratcoski | F | - | - | |
Frederick D. Hay | M | 79 | - | |
Marc D. Doubleday | M | 65 |
Northfield Laboratories, Inc.
Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | 21 ans |
Mathew E. Carter | M | - |
PepsiAmericas, Inc.
PepsiAmericas, Inc. Beverages: Non-AlcoholicConsumer Non-Durables PepsiAmericas, Inc. makes sells and delivers a broad portfolio of Pepsi-Cola core brands, Cadbury beverages and other national and regional brands in U.S. locations as well as Puerto Rico, Jamaica, Barbados, the Bahamas, Trinidad and Tobago, Poland, Hungary, the Czech Republic and the Republic of Slovakia. PepsiCo, Inc. holds a 57 percent equity interest in PepsiAmericas. The company was founded in 1962 and is headquartered in Minneapolis, MN. | 11 ans |
Robert McGinnis | M | 60 |
Northfield Laboratories, Inc.
Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | 12 ans |
Alan L. Heller | M | 70 |
Northfield Laboratories, Inc.
Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | 3 ans |
Paul M. Ness | M | 78 |
Northfield Laboratories, Inc.
Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | 7 ans |
Sophia H. Twaddell | F | 72 |
Northfield Laboratories, Inc.
Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | 6 ans |
Andrew R. Stark | M | 60 |
PepsiAmericas, Inc.
PepsiAmericas, Inc. Beverages: Non-AlcoholicConsumer Non-Durables PepsiAmericas, Inc. makes sells and delivers a broad portfolio of Pepsi-Cola core brands, Cadbury beverages and other national and regional brands in U.S. locations as well as Puerto Rico, Jamaica, Barbados, the Bahamas, Trinidad and Tobago, Poland, Hungary, the Czech Republic and the Republic of Slovakia. PepsiCo, Inc. holds a 57 percent equity interest in PepsiAmericas. The company was founded in 1962 and is headquartered in Minneapolis, MN. | 13 ans |
Blaine A. Metzger | M | 67 | 4 ans | |
Jay Kleiman | M | - |
Northfield Laboratories, Inc.
Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | - |
Eva Essig | F | - |
Northfield Laboratories, Inc.
Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | - |
Constance R. Johnsen | F | 66 | 14 ans | |
Sharon Brady | F | 73 | - | |
Louis Joseph Corna | M | 77 |
Whitman Corp.
| 7 ans |
Kent S. Belasco | M | 72 | 25 ans | |
O. Ralph Edwards | M | 89 | 16 ans | |
Gerald A. Kien | M | 92 |
Snap-on Tools Co. LLC
Snap-on Tools Co. LLC Tools & HardwareConsumer Durables Snap-on Tools Co. LLC manufactures tools & industrial equipment. The firm offers ten different sockets that would 'snap on' to five interchangeable wrench. The company was founded in 1920 and is headquartered in Kenosha, Wisconsin. | 1 ans |
Laurel A. Omert | M | 67 |
Northfield Laboratories, Inc.
Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | 4 ans |
Edward C. Wood | M | 79 |
Northfield Laboratories, Inc.
Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | 4 ans |
James P. Hotchkiss | M | 67 | 18 ans | |
Kimberly J. McGarry | F | 50 | - | |
Lars Nyberg | M | 73 | 5 ans | |
Jarobin Gilbert | M | 78 |
PepsiAmericas, Inc.
PepsiAmericas, Inc. Beverages: Non-AlcoholicConsumer Non-Durables PepsiAmericas, Inc. makes sells and delivers a broad portfolio of Pepsi-Cola core brands, Cadbury beverages and other national and regional brands in U.S. locations as well as Puerto Rico, Jamaica, Barbados, the Bahamas, Trinidad and Tobago, Poland, Hungary, the Czech Republic and the Republic of Slovakia. PepsiCo, Inc. holds a 57 percent equity interest in PepsiAmericas. The company was founded in 1962 and is headquartered in Minneapolis, MN. | 16 ans |
Larry Young | M | 69 |
PepsiAmericas, Inc.
PepsiAmericas, Inc. Beverages: Non-AlcoholicConsumer Non-Durables PepsiAmericas, Inc. makes sells and delivers a broad portfolio of Pepsi-Cola core brands, Cadbury beverages and other national and regional brands in U.S. locations as well as Puerto Rico, Jamaica, Barbados, the Bahamas, Trinidad and Tobago, Poland, Hungary, the Czech Republic and the Republic of Slovakia. PepsiCo, Inc. holds a 57 percent equity interest in PepsiAmericas. The company was founded in 1962 and is headquartered in Minneapolis, MN. | 8 ans |
Niels W. Johnsen | M | 101 |
Trans Union LLC
Trans Union LLC Internet Software/ServicesTechnology Services Trans Union LLC provides information and risk management solutions to individual consumers and businesses. Its products and solutions include customer credit reporting, marketing and audience segmentation, customer acquisition, fraud and ID management, analytics and consulting, portfolio management, healthcare revenue cycle management, investigations and collections, customer engagement solutions and data breach services. The company was founded in 1968 and is headquartered in Chicago, IL. | 8 ans |
David A. Savner | M | 79 |
Northfield Laboratories, Inc.
Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | 11 ans |
Vernon A. Brunner | M | 83 | 12 ans | |
Susan C. Edwards | F | - | 8 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 100 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Bruce S. Chelberg
- Réseau Personnel